Vpriv Takeda Pharmaceuticals International AG Ireland Branch · Authorised · authorised 26 Aug 2010 · ATC A16AB10
Therapeutic indication (EMA)
Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
Active substance
Velaglucerase alfa
- SFDA 1
- US FDA 2
- EMA 1
- Health Canada 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| VPRIV 40 U POWDER FOR SOLUTION FOR INFUSION | 400 U | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 6118.55 | NCE · Prescription | Takeda Pharmaceuticals International AG | Valid |
Indications — CHI Daman Drug Formulary
GAUCHER DISEASE
US FDA United States — FDA approvals (Drugs@FDA)
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| VPRIV | 02357119 | 400 UNIT / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | TAKEDA CANADA INC |
Safety signals and safety-related labeling changes
- US FDA 10 Jul 2024 VPRIV — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.